首页 > 

365 taya casino

2025-01-22
Abstaining from cigarettes for just one week can extend a smoker’s life by a day, research suggests. A study by University College London estimates that each cigarette, on average, steals about 20 minutes of life from a smoker. This is a higher figure than previously thought, with earlier research suggesting that each cigarette cuts a smoker’s life short by 11 minutes. The research, which was commissioned by the Department of Health and Social Care, found that men lost 17 minutes of life with every cigarette they smoke while women lost 22 minutes. The estimates were calculated using figures from the British Doctors Study, which collected data on male mortality over 50 years, and the Million Women Study, covering women’s mortality data from 1996 to 2011.MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®1, 89Zr- girentuximab) kidney cancer imaging2. TLX250-CDx is an investigational PET3 drug product for the non-invasive diagnosis and characterization of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix’s successful urology imaging franchise. The FDA is expected to advise the PDUFA4 goal date following the 60-day administrative review of the application. Kevin Richardson, Chief Executive Officer, Precision Medicine at Telix, stated, “We are pleased to be progressing the BLA for TLX250-CDx, which has been granted Breakthrough designation, and may therefore be eligible for priority review. Telix continues to target a full U.S. commercial launch in 2025 addressing a major unmet medical need for patients with suspected ccRCC.” About TLX250-CDx TLX250-CDx (Zircaix®1) is an investigational PET agent that is under development for the diagnosis and characterization of ccRCC. Telix’s pivotal Phase III ZIRCON trial (ClinicalTrials.gov ID: NCT03849118 ) evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% positive-predictive value for ccRCC across three independent radiology readers5. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterizing ccRCC. Confidence intervals exceeded expectations amongst all three readers, showing evidence of high accuracy and consistency of interpretation. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)6, by the Australian Therapeutic Goods Administration (TGA) 7, and by Health Canada8. No other Telix product has received a marketing authorization in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn . Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Illuccix® and Zircaix® 1 names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. 1 Brand name subject to final regulatory approval. 2 Telix ASX disclosure 31 July 2024. The FDA requested additional data demonstrating adequate sterility assurance during dispensing of TLX250-CDx in the radiopharmacy production environment. 3 Positron emission tomography. 4 Prescription Drug User Fee Act. 5 Shuch et al. Lancet Oncol. 2024. Telix ASX disclosures 7 November 2022. 6 Telix ASX disclosure 20 December 2021. 7 Telix ASX disclosure 2 November 2021. 8 Telix ASX disclosure 14 October 2022.None365 taya casino

Trump urges high court to freeze TikTok ban

TD an outlier in Q4 with suspended guidance as other banks look to rosier 2025By Vanessa G. Sánchez, KFF Health News (TNS) LOS ANGELES — President-elect Donald Trump’s promise of mass deportations and tougher immigration restrictions is deepening mistrust of the health care system among California’s immigrants and clouding the future for providers serving the state’s most impoverished residents. At the same time, immigrants living illegally in Southern California told KFF Health News they thought the economy would improve and their incomes might increase under Trump, and for some that outweighed concerns about health care. Community health workers say fear of deportation is already affecting participation in Medi-Cal, the state’s Medicaid program for low-income residents, which was expanded in phases to all immigrants regardless of residency status over the past several years. That could undercut the state’s progress in reducing the uninsured rate, which reached a record low of 6.4% last year. Immigrants lacking legal residency have long worried that participation in government programs could make them targets, and Trump’s election has compounded those concerns, community advocates say. The incoming Trump administration is also expected to target Medicaid with funding cuts and enrollment restrictions , which activists worry could threaten the Medi-Cal expansion and kneecap efforts to extend health insurance subsidies under Covered California to all immigrants. “The fear alone has so many consequences to the health of our communities,” said Mar Velez , director of policy with the Latino Coalition for a Healthy California. “This is, as they say, not their first rodeo. They understand how the system works. I think this machine is going to be, unfortunately, a lot more harmful to our communities.” Alongside such worries, though, is a strain of optimism that Trump might be a boon to the economy, according to interviews with immigrants in Los Angeles whom health care workers were soliciting to sign up for Medi-Cal. Since Election Day, community health worker Yanet Martinez said, people are more reluctant to hear her pitch for subsidized health insurance or cancer prevention screenings. “They think I’m going to share their information to deport them,” Martinez said. (Vanessa G. Sánchez/KFF Health News/TNS) Clinics and community health workers encourage immigrants to enroll for health coverage through Medi-Cal and Covered California. But workers have noticed that fear of deportation has chilled participation. (Vanessa G. Sánchez/KFF Health News/TNS) Community health workers like Yanet Martinez encourage people to enroll for health benefits. But many California immigrants fear that using subsidized services could hurt their chances of obtaining legal residency. (Vanessa G. Sánchez/KFF Health News/TNS) Since Election Day, community health worker Yanet Martinez said, people are more reluctant to hear her pitch for subsidized health insurance or cancer prevention screenings. “They think I’m going to share their information to deport them,” Martinez said. (Vanessa G. Sánchez/KFF Health News/TNS) Selvin, 39, who, like others interviewed for this article, asked to be identified by only his first name because he’s living here without legal permission, said that even though he believes Trump dislikes people like him, he thinks the new administration could help boost his hours at the food processing facility where he works packing noodles. “I do see how he could improve the economy. From that perspective, I think it’s good that he won.” He became eligible for Medi-Cal this year but decided not to enroll, worrying it could jeopardize his chances of changing his immigration status. “I’ve thought about it,” Selvin said, but “I feel like it could end up hurting me. I won’t deny that, obviously, I’d like to benefit — get my teeth fixed, a physical checkup.” But fear holds him back, he said, and he hasn’t seen a doctor in nine years. It’s not Trump’s mass deportation plan in particular that’s scaring him off, though. “If I’m not committing any crimes or getting a DUI, I think I won’t get deported,” Selvin said. Petrona, 55, came from El Salvador seeking asylum and enrolled in Medi-Cal last year. She said that if her health insurance benefits were cut, she wouldn’t be able to afford her visits to the dentist. A street food vendor, she hears often about Trump’s deportation plan, but she said it will be the criminals the new president pushes out. “I’ve heard people say he’s going to get rid of everyone who’s stealing.” Although she’s afraid she could be deported, she’s also hopeful about Trump. “He says he’s going to give a lot of work to Hispanics because Latinos are the ones who work the hardest,” she said. “That’s good, more work for us, the ones who came here to work.” Newly elected Republican Assembly member Jeff Gonzalez, who flipped a seat long held by Democrats in the Latino-heavy desert region in the southeastern part of the state, said his constituents were anxious to see a new economic direction. “They’re just really kind of fed up with the status quo in California,” Gonzalez said. “People on the ground are saying, ‘I’m hopeful,’ because now we have a different perspective. We have a businessperson who is looking at the very things that we are looking at, which is the price of eggs, the price of gas, the safety.” Related Articles National Politics | Mexico tests cellphone app allowing migrants to send alert if they are about to be detained in US National Politics | Trump wants mass deportations. For the agents removing immigrants, it’s a painstaking process National Politics | Immigration agency deports highest numbers since 2014, aided by more flights National Politics | Advocates train immigrants to ‘prepare to stay’ in the US under Trump National Politics | Immigration drives US population growth to highest rate in 23 years as residents pass 340 million Gonzalez said he’s not going to comment about potential Medicaid cuts, because Trump has not made any official announcement. Unlike most in his party, Gonzalez said he supports the extension of health care services to all residents regardless of immigration status . Health care providers said they are facing a twin challenge of hesitancy among those they are supposed to serve and the threat of major cuts to Medicaid, the federal program that provides over 60% of the funding for Medi-Cal. Health providers and policy researchers say a loss in federal contributions could lead the state to roll back or downsize some programs, including the expansion to cover those without legal authorization. California and Oregon are the only states that offer comprehensive health insurance to all income-eligible immigrants regardless of status. About 1.5 million people without authorization have enrolled in California, at a cost of over $6 billion a year to state taxpayers. “Everyone wants to put these types of services on the chopping block, which is really unfair,” said state Sen. Lena Gonzalez, a Democrat and chair of the California Latino Legislative Caucus. “We will do everything we can to ensure that we prioritize this.” Sen. Gonzalez said it will be challenging to expand programs such as Covered California, the state’s health insurance marketplace, for which immigrants lacking permanent legal status are not eligible. A big concern for immigrants and their advocates is that Trump could reinstate changes to the public charge policy, which can deny green cards or visas based on the use of government benefits. “President Trump’s mass deportation plan will end the financial drain posed by illegal immigrants on our healthcare system, and ensure that our country can care for American citizens who rely on Medicaid, Medicare, and Social Security,” Trump spokesperson Karoline Leavitt said in a statement to KFF Health News. During his first term, in 2019, Trump broadened the policy to include the use of Medicaid, as well as housing and nutrition subsidies. The Biden administration rescinded the change in 2021. KFF, a health information nonprofit that includes KFF Health News, found immigrants use less health care than people born in the United States. And about 1 in 4 likely undocumented immigrant adults said they have avoided applying for assistance with health care, food, and housing because of immigration-related fears, according to a 2023 survey . Another uncertainty is the fate of the Affordable Care Act, which was opened in November to immigrants who were brought to the U.S. as children and are protected by the Deferred Action Childhood Arrivals program. If DACA eligibility for the act’s plans, or even the act itself, were to be reversed under Trump, that would leave roughly 40,000 California DACA recipients, and about 100,000 nationwide , without access to subsidized health insurance. On Dec. 9, a federal court in North Dakota issued an order blocking DACA recipients from accessing Affordable Care Act health plans in 19 states that had challenged the Biden administration’s rule. Clinics and community health workers are encouraging people to continue enrolling in health benefits. But amid the push to spread the message, the chilling effects are already apparent up and down the state. “¿Ya tiene Medi-Cal?” community health worker Yanet Martinez said, asking residents whether they had Medi-Cal as she walked down Pico Boulevard recently in a Los Angeles neighborhood with many Salvadorans. “¡Nosotros podemos ayudarle a solicitar Medi-Cal! ¡Todo gratuito!” she shouted, offering help to sign up, free of charge. “Gracias, pero no,” said one young woman, responding with a no thanks. She shrugged her shoulders and averted her eyes under a cap that covered her from the late-morning sun. Since Election Day, Martinez said, people have been more reluctant to hear her pitch for subsidized health insurance or cancer prevention screenings. “They think I’m going to share their information to deport them,” she said. “They don’t want anything to do with it.” This article was produced by KFF Health News , which publishes California Healthline , an editorially independent service of the California Health Care Foundation . ©2024 KFF Health News. Distributed by Tribune Content Agency, LLC.

Vance takes on a more visible transition role, working to boost Trump’s most contentious picksPollard Banknote: A Winning Ticket At 11x Forward Earnings

Finland beats US 4-3 in OT in world junior hockey; Canada rebounds from loss to top Germany 3-0A childhood friend of the Quebec man killed in a Florida boat explosion earlier this week says one of the victim’s sisters was among the other six passengers injured in the blast. Thi Cam Nhung Lê says she grew up with Sebastien Gauthier in Quebec City and considered him her best friend. Lê says Gauthier’s older sister was also on the boat in Florida’s Broward County when it exploded and she was taken to a hospital. She says Gauthier’s family was in Florida to celebrate the holidays and that his sudden death feels “unimaginable.” A video posted on social media Monday shows the vessel engulfed in flames following the explosion, with a thick column of black smoke billowing into the sky. The Florida Fish and Wildlife Conservation Commission has confirmed that Gauthier died of his injuries, saying a preliminary investigation shows the 37-foot vessel exploded after its engines were started. Lê remembers Gauthier as someone who was always smiling and says she is waiting for answers about what led to her friend’s death.

CENTURION: An emotional Temba Bavuma hailed the character of his team after South Africa qualified for the World Test championship final with a dramatic two-wicket win over Pakistan on the fourth day of the first Test at SuperSport Park on Sunday. Needing 148 to win, South Africa crashed to 99 for eight owing to superb bowling by Mohammad Abbas. But Kagiso Rabada turned batting hero as he and Marco Jansen took South Africa to victory with an unbeaten ninth wicket partnership of 51. Rabada, so often a match-winner as a bowler, went on the attack as a batsman, hitting an unbeaten 31 off 26 balls, while Jansen provided solid support in making 16 not out. “It is an emotional moment for me,” South African captain Bavuma said at the post-match presentation. “As a team, we have overcome a lot. We haven’t been super-dominant with our performances, we haven’t been ruthless but we have always found a way to ensure the result was on our side. “Today was testament to that. It speaks a lot to the talent and character of the group.” South Africa’s win meant that only one of Australia and India can qualify for the final at Lord’s in June. Pakistan captain Shan Masood said he was proud of the effort of his players but lamented the failure to take ruthless advantage of their opportunities. “Twice we had them eight down and with the bat we could have extended our first innings and could have extended our lead (in the second innings). We have to learn to seize the moments.” ‘The only spike’ Masood said Abbas, playing in his first Test in more than three years, had been “sensational”. The 34-year-old Abbas took a career-best six for 54. He bowled unchanged for 19.3 overs—four of them on Saturday when he took his first two wickets—in a spell of unremitting accuracy on a pitch which gave seam bowlers help throughout the match. Man of the match Aiden Markram and Bavuma batted solidly at the start of the day after resuming on 27 for three. However, Markram was bowled by Abbas for 37 by a virtually unplayable ball which kept low and seamed back off the pitch. Bavuma and David Bedingham added another 34 runs until Bavuma uncharacteristically charged down the pitch at Abbas and was given out caught behind for 40. He walked off immediately but Ultra Edge technology showed the only ‘spike’ was when the ball brushed his trouser pocket. It was the first of four wickets which fell for three runs in 12 balls. Naseem Shah bowled Kyle Verreynne and Abbas had Bedingham and Corbin Bosch caught behind off successive deliveries. Rabada and Jansen saw South Africa through to lunch at 116 for eight—then polished off the match in just 5.3 overs after the interval, with each stroke cheered by the home spectators. Both sides have a short break before they meet for the second and final Test in Cape Town on January 3. — AFP

Previous: xo jili casino
Next: 98 jili casino login